

***In vivo* molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3**

Maria do Carmo Costa, PhD,^{1*} Maria Radzwion, BSc,¹ Hayley S. McLoughlin, PhD,¹ Naila S. Ashraf, MSc,¹ Svetlana Fischer, MSc,¹ Vikram G. Shakkottai, MD, PhD,^{1,2} Patrícia Maciel, PhD,³ Henry L. Paulson, MD, PhD,¹ Gülin Öz, PhD,⁴

¹Department of Neurology, University of Michigan, Ann Arbor, MI, USA; ²Departments of Molecular & Integrative Physiology and of Medicine, University of Michigan, Ann Arbor, MI; ³Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Portugal; ⁴Center for Magnetic Resonance Research, Department of Radiology, Medical School, University of Minnesota, Minneapolis, MN, USA.

***Corresponding author**

Maria do Carmo Costa, Ph.D.

Department of Neurology, University of Michigan

A. Alfred Taubman Biomedical Sciences Research Building, Room 4027

109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA

Phone: +1 734-764-4094

E-mail address: mariadoc@med.umich.edu

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/mds.28140](https://doi.org/10.1002/mds.28140)

Word count: 4846 words

Running title: Neurochemical profiles of SCA3 transgenic mice

Keywords: Machado-Joseph disease; ataxin-3; polyglutamine; demyelination; magnetic resonance spectroscopy

Abstract

Background: No treatment exists for the most common dominantly inherited ataxia Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3). Successful evaluation of candidate therapeutics will be facilitated by validated noninvasive biomarkers of disease pathology recapitulated by animal models.

Objective: We sought to identify shared *in vivo* neurochemical signatures in two mouse models of SCA3 that reflect the human disease pathology.

Methods: Cerebellar neurochemical concentrations in homozygous YACMJD84.2 (Q84/Q84) and hemizygous CMVMJD135 (Q135) mice were measured by *in vivo* magnetic resonance spectroscopy at 9.4 tesla. To validate the neurochemical biomarkers, levels of neurofilament medium (NFL, indicator of neuroaxonal integrity) and myelin basic protein (MBP, indicator of myelination) were measured in cerebellar lysates from a subset of mice and patients with SCA3. Finally, NFL and MBP levels were measured in cerebellar extracts of Q84/Q84 mice upon silencing of the mutant *ATXN3* gene.

Results: Both Q84/Q84 and Q135 mice displayed lower *N*-acetylaspartate than wild-type littermates, indicating neuroaxonal loss/dysfunction, and lower *myo*-inositol and total choline, indicating disturbances in phospholipid membrane metabolism and demyelination. Cerebellar

NFL and MBP levels were accordingly lower in both models, as well as in the cerebellar cortex of patients with SCA3 than controls. Importantly, *N*-acetylaspartate and total choline correlated with NFL and MPB, respectively, in Q135 mice. Long-term sustained RNAi-mediated reduction of ATXN3 levels increased NFL and MBP in Q84/Q84 cerebella.

Conclusions: *N*-acetylaspartate, *myo*-inositol and total choline levels in the cerebellum are candidate biomarkers of neuroaxonal and oligodendrocyte pathology in SCA3, aspects of pathology that are reversible by RNAi therapy.

Introduction

With increasing human lifespan, numerous age-related neurodegenerative diseases of diverse etiologies are becoming more prevalent. Nine such disorders are caused by an expanded CAG triplet repeat in genes that encode an abnormally longer polyglutamine (polyQ) tract in the respective disease proteins^{1,2}. Since the identification of these disease genes in the 1990s, increased understanding of the molecular basis of polyQ disorders led to several potentially efficacious therapies that were tested in animal models. Nucleotide-based reduction of CAG-containing transcripts using nucleic acids has proven to be a particularly compelling therapeutic strategy for polyQ diseases in pre-clinical studies³⁻⁷, and clinical trials are underway for Huntington disease using antisense oligonucleotides (ASOs)⁸. Other gene and pharmacological therapeutic approaches for polyQ disorders are also in the pipeline⁹⁻¹¹. Readiness for these upcoming clinical trials depends on the availability of disease biomarkers that allow noninvasive monitoring of aspects of cerebral disease pathology to assess therapeutic efficacy.

Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is a polyQ disease caused by an expanded CAG repeat in the *ATXN3* gene¹² that leads to selective dysfunction and loss of neurons of specific nuclei in the cerebellum, brainstem, midbrain, spinal cord, and peripheral nerves^{9-11, 13-21}. The disease manifests in patients with SCA3 as ataxia and a variable degree of other manifestations, including extrapyramidal signs, neuropathy, ophthalmoplegia, and muscle atrophy²²⁻²⁶.

SCA3 is one of the polyQ diseases for which clinical trials are forthcoming. ASOs²⁷⁻³⁰, other RNA interference molecules^{31, 32}, and pharmacological agents such as the selective

serotonin reuptake inhibitor, citalopram³³⁻³⁵, showed preclinical efficacy to mitigate molecular, pathological, and phenotypic SCA3-like signs in transgenic mice.

The success of upcoming human trials of these agents will be facilitated by the availability of validated noninvasive biomarkers of cerebral and cerebellar pathology. To this end, a number of studies have demonstrated an ability to detect macro- and micro-structural and neurochemical abnormalities noninvasively by magnetic resonance imaging^{14, 36-38} (MRI) and spectroscopy³⁹⁻⁴¹ (MRS) in SCA3. While macrostructural disease-associated changes detectable by conventional MRI clearly mark tissue loss, other MR metrics may allow noninvasive monitoring of aspects of pathology that precede cell loss and atrophy, and hence may be reversible with treatments. However, such MR metrics need to be validated by comparing them to tissue pathology.

Here, using MRS at 9.4 tesla (T), we sought to identify cerebellar neurochemical signatures in two mouse models of SCA3 that are extensively used in SCA3 preclinical trials: homozygous YACMJD84.2 (Q84/Q84)^{31, 42} and hemizygous CMVMJD135 (Q135)⁴³ mice. We assessed two models to identify the common neurochemical abnormalities that may provide signatures of SCA3 pathology. To validate identified potential neurochemical biomarkers and determine which aspects of pathology they reflect, we evaluated cerebellar demyelination and neuroaxonal pathology in the same mice, as well as brain tissue from patients with SCA3. Finally, we determined whether RNAi-mediated silencing of the SCA3 gene reverses cerebellar demyelination and axonopathy in the Q84/Q84 model, since evidence of reversibility would suggest noninvasive myelin and neuronal markers could reflect therapeutic efficacy in future trials.

Materials and Methods

Experimental design

The study was designed to assess MRS neurochemical profiles of two transgenic models frequently used in preclinical trials for SCA3– homozygous YACMJD84.2 (Q84/Q84)⁴² and hemizygous CMVMJD135 (Q135)⁴³ mice. All animal procedures were approved by the University of Michigan Committee on the Use and Care of Animals (Protocol PRO00003836) and by the University of Minnesota Institutional Animal Care and Use Committee (Protocol 1207A17510). Groups of Q84/Q84 (N=14 (7F/7M), 9-17 month-old) and their littermate non-transgenic (wt) mice (N=11 (7F/4M), 11-18 month-old), and Q135 (N=9 (3F/6M), 8-16 month-old) and their wt littermates (N=8 (5F/3M), 10-16 month-old) in the C57Bl6/J background (Supplementary Table 1) were scanned. Mice were housed in cages of maximum five animals and maintained in a standard 12-hours light/dark cycle with food and water *ad libitum*.

Peripheral blood was collected by tail vein snip for a subgroup of Q84/Q84 mice (N=5) and littermate controls (N=4) to analyze liver profiles. Mice were shipped from the University of Michigan to the University of Minnesota for MR scanning, 2-4 weeks prior to scans. After MR scanning, mice were deeply anesthetized with sodium pentobarbital (100mg/kg i.p.), sacrificed by transcardial perfusion with pH 7.4 phosphate buffered saline and tissues were sent back to the University of Michigan for *post-mortem* analyses for demyelination (myelin basic protein (MBP), Luxol fast blue), axonopathy (neurofilament medium (NFL)), assessment of molecular layer thickness and Purkinje cell count.

To investigate if the pathological features identified in SCA3 mice reflect the human condition we obtained deidentified frozen and fixed samples from the cerebellar cortex of autopsied brains from molecularly confirmed SCA3 (N=6) and control individuals (N=5) from the University of Michigan Brain Bank. (See Supplementary Table 2 for demographic information).

To verify if RNAi-mediated depletion of human mutant ATXN3 rescues cerebellar molecular phenotypes in SCA3 mice, we used protein lysates from cerebella of end-stage Q84/Q84 mice (10-20 month old) that, at 6-8 weeks-of-age, were injected in the deep cerebellum nuclei with an adeno-associated virus (AAV2/1) encoding an artificial microRNA targeting mutant *ATXN3* (miRATXN3) (N=10) or with vehicle (N=10)³¹.

Mouse genotyping and (CAG)_n size assessment

Genotyping was performed by PCR using DNA isolated from tail biopsy at weaning as previously described^{42, 43}. (CAG)_n size in Q84/Q84 and Q135 mice (Supplementary Table 1), and in SCA3 and control individuals (Supplementary Table 2) was determined at Laragen Inc. by gene fragment analysis.

In vivo measurements

Magnetic resonance (MR) protocol

Procedures for anesthesia and MR scanning were identical to our prior studies^{44, 45}. Mice were induced with 3-4% isoflurane and were maintained anesthetized with 1.5-2% isoflurane during scanning. Body temperature was maintained at 36-37°C and respiration rate at ~70-100 breaths per minute. The scanning time for each animal was approximately 50 minutes. MR scans were

performed using a quadrature surface RF coil and a 9.4 T/31 cm magnet (Magnex Scientific, Abingdon, UK) interfaced to an Agilent console (Agilent, Inc., Palo Alto, CA, USA). A cerebellar volume-of-interest (VOI, 5-7 μ l, placed based on anatomical landmarks to avoid inclusion of cerebrospinal fluid (CSF), Fig. 1A, 2A) was selected on coronal and sagittal multi-slice images obtained with a rapid acquisition with relaxation enhancement (RARE) sequence⁴⁶. First- and second-order shims were adjusted using FASTMAP⁴⁷. Localized ¹H MR spectra were acquired with a localization by adiabatic selective refocusing (LASER) sequence (echo time TE=15ms, repetition time TR=5s, 256 averages)⁴⁸, as described previously^{44, 45}. Spectra were saved as single scans, which were frequency and phase corrected⁴⁹. Frequency drifts were corrected in the time domain after peak picking in frequency domain (the tCr peak at 3ppm) by using the first transient as reference. Similarly, phase correction was done in the time domain by calculating the phase difference between the reference (first) transient and other transients. Transients that showed evidence for motion (substantial deviations in frequency, linewidth, signal-to-noise ratio (SNR), loss of water suppression efficiency relative to other transients) were excluded prior to averaging⁴⁹. In the 23 spectra obtained from the Q84/Q84 cohort (mice that were included in the MRS analysis), 1-2 shots (out of 256) were excluded in 3 spectra, 45 shots were excluded in one spectrum and the acquisition had to be stopped due to gasping in one mouse, generating 110 usable shots. The remaining 18 spectra had all 256 shots. In the 14 spectra obtained from the Q135 cohort (mice that were included in the MRS analysis), 5 shots were excluded in one spectrum and 93 shots were excluded in another spectrum. The remaining 12 spectra had all 256 shots. Finally, the averaged spectra were corrected for eddy current effects using the unsuppressed water signal acquired from the same VOI⁵⁰.

Metabolite quantification

Metabolites were quantified using LCModel⁵¹ relative to unsuppressed water spectra acquired from the same VOI, as described before^{44, 45}. Reliable concentrations were selected based on Cramér-Rao lower bounds (CRLB) criteria (quantification with $CRLB \leq 20\%$ in the majority of the spectra). Alanine, aspartate, glycine and scyllo-inositol were excluded from final analysis based on these criteria. If the correlation between two metabolites was consistently high (correlation coefficient < -0.5), their sum was reported⁵². Strong negative correlation was found between creatine and phosphocreatine and between glycerophosphocholine + phosphocholine, therefore total creatine (tCr) and total choline (tCho) were reported. Based on these reliability criteria, 14 concentrations were evaluated: ascorbate (Asc), γ -aminobutyric acid (GABA), glucose (Glc), glutamine (Gln), glutamate (Glu), glutathione (GSH), *myo*-inositol (*myo*-Ins), lactate (Lac), *N*-acetylaspartate (NAA), *N*-acetylaspartylglutamate (NAAG), phosphoethanolamine (PE), taurine (Tau), tCr and tCho.

Liver profile

Peripheral blood collected from mouse tail vein snip was immediately centrifuged at maximum speed and serum was collected and stored at -80°C . Serum samples were thawed, centrifuged and supernatants were loaded in VetScan[®] Mammalian Liver Profile reagent rotors (Abaxis, Inc.), which in turn were read in a VetScan Chemistry Analyzer providing quantitative determinations of albumin (ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), bile acids (BA), blood urea nitrogen (BUN), total cholesterol (CHOL), gamma glutamyl transferase (GGT).

Post-mortem measurements

Western blot

Extracts of soluble proteins in RIPA buffer from mouse cerebella or human cerebellar cortex were obtained using an established protocol³¹. Lysates from soluble protein fractions were resolved on 10% SDS-PAGE gels, and corresponding PVDF membranes were incubated overnight at 4°C with primary antibodies: rat anti-MBP (1:1000; MCA409S, AbDSerotec), mouse anti-160kD NFL (1:1000; ab7794, Abcam), rabbit anti- α -tubulin (1:5000; 2144S, Cell Signaling), mouse anti-GAPDH (1:10000; MAB374, Millipore), and rabbit anti-MJD (1:20000). Bound primary antibodies were visualized by peroxidase-conjugated anti-rat, anti-mouse or anti-rabbit secondary antibodies (1:10000; Jackson Immuno Research Laboratories) followed by treatment with ECL-plus reagent (PerkinElmer) and exposure to autoradiography films. Band intensity was quantified by densitometry using ImageJ.

Luxol fast blue staining

Five- μ m paraffin sections of cerebellar lobules from aged-matched patients with SCA3 and unaffected individuals were simultaneously deparaffinized in xylene and stained with Luxol fast blue. Briefly, sections were dewaxed in xylene, washed in absolute ethanol and 95% ethanol, stained overnight in 0.1% Luxol fast blue in acidic 95% ethanol, washed in 95% ethanol, differentiated in 0.05% lithium carbonate solution for 30 seconds, rinsed in distilled water and washed in 70% and 90% ethanol, washed in absolute ethanol, fixed in xylene and mounted in DPX mountant. Slides were imaged in a bright-field Olympus BX51 microscope.

Immunofluorescence staining

Left mouse brain hemispheres were fixed overnight in 4% paraformaldehyde, embedded in 30% sucrose/phosphate-buffered saline, and sectioned on a sledge microtome (SM200R; Leica Biosystems). Triple immunofluorescent labelling of free-floating 40- μ m sagittal sections was conducted as previously³¹, using rat anti-MBP (1:50), mouse anti-NFL (1:500), rabbit anti-ATXN3 (anti-MJD 1:2000), secondary mouse Alexa Fluor 488, rat Alexa Fluor 568 antibodies, and rabbit Alexa Fluor 647 (Invitrogen), and 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). Sections were mounted with Prolong Gold Antifade Reagent (Invitrogen) and imaged in an Olympus IX71 microscope. Measurements of molecular layer thickness were made as previously described⁵³. Briefly, using images from the triple immunostaining, two measurements were made at the depth of the primary fissure and two others at 100 μ m from there. Purkinje neuron cell counts were obtained as the total number of neurons in the region of the primary fissure folium.

Liver Hematoxylin & Eosin (H&E) histology

Livers from four Q84/Q84 mice and one littermate control used in the MRS studies were fixed in 10% formalin, paraffin embedded, and four- μ m paraffin sections were stained with H&E and observed in a bright field microscope.

Statistical Analysis

Characteristics of transgenic and control groups were compared using the two-tailed, unpaired Student's t-test for age and spectral quality metrics (linewidth and SNR obtained from LCModel) and chi-square test for sex. Levels of neurochemicals and proteins were compared between the transgenic and control groups using Student's t-test as all distributions were normal and showed

homogeneous variances. Linear regression analyses were performed to evaluate the relationship between neurochemical concentrations and protein levels using Pearson correlation. A $P < 0.05$ was considered statistically significant in all analyses. P -values were not corrected across the multiple metabolites due to the exploratory nature of our analysis and to avoid inflation of type II errors. Data were analyzed using IBM SPSS Statistics 22 software.

Results

Homozygous Q84/Q84 and hemizygous Q135 transgenic mice show shared neurochemical alterations in the cerebellum as measured by *in vivo* MRS

Q84/Q84 and Q135 SCA3 transgenic mice show early onset of SCA3-like phenotypes starting around 6 weeks-of-age^{31, 43} and therefore are often used in preclinical trials^{31, 35, 43, 53-56}. We investigated common neurochemical biomarkers in these two models that could serve as outcome measures in preclinical trials.

Because no *in vivo* MRS studies were previously conducted in SCA3 mouse models, we obtained MR spectra at ultra-high field from the cerebellar vermis of symptomatic homozygous Q84/Q84, hemizygous Q135 and their littermate wt controls at an age when Purkinje cell dysfunction and pathology was previously shown in related transgenic mouse models^{35, 53}. Two Q84/Q84 mice, two Q135 mice and one Q135 wt control were found to have an abnormal high Gln profile that was previously described in the brains of mice derived from the C57BL/6 strain^{57, 58}. The abnormal profile consisted of 2-3 fold higher Gln, 35-60% lower myo-Ins and 10-35% lower Tau relative to other wt or SCA3 mice in the same group. Because this profile results from

portosystemic shunting in the liver⁵⁷, which causes alterations in gene expression in many organs, these 5 mice were excluded from further analysis.

SCA3 transgenic mice and their wt controls included in the MRS analyses were matched for age (Q84/Q84 13.4±2.1 (mean±SD) vs. wt 13.7±2.0 months, $P=0.71$; Q135 14.7±3.0 vs. wt 15.1±2.3 months, $P=0.77$) and sex (Q84/Q84 7M/5F vs. wt 4M/7F, $P=0.41$; Q135 4M/3F vs. wt 2M/5F, $P=0.59$). In addition, spectral quality was comparable in the SCA3 vs. wt groups (Linewidths Q84/Q84 10.0±2.2 (mean±SD) vs. wt 9.7±1.5 Hz, $P=0.67$; Q135 12.6±4.1 vs. wt 10.3±1.5 Hz, $P=0.19$; SNR Q84/Q84 30.6±7.6 vs. wt 31.7±4.0, $P=0.67$; Q135 28.7±3.5 vs. wt 27.4±3.2, $P=0.49$). Finally, structural images did not indicate substantial atrophy in SCA3 vs. wt mice (Figures 1A and 2A) and the VOI did not contain CSF. Therefore, group differences observed in the neurochemical profiles could not be due to group differences in age, sex, atrophy or spectral quality.

Neurochemical profiles of Q84/Q84 mice (N=12), with predominant CAG repeat size ranging from 69 to 74 triplets (Supplementary Table 1), showed significantly higher Gln and lower levels of total NAA (tNAA), NAA, Glc, myo-Ins, Tau, and tCho compared to wt littermates (N=11) (Figure 1A,B). Because sex matching was imperfect between groups and the severity of the phenotype may be sex-dependent in SCA3 mice, we further investigated the neurochemical profiles of male and female mice only. We observed the same neurochemical trends in male and female mice analyzed separately, except for the myo-Ins difference that appeared to be primarily driven by female mice (Supplementary Figure 1). This was consistent with a lack of sex-differences of the motor phenotype in Q84/Q84 mice³¹. To investigate if the Gln levels in Q84/Q84 mice that were almost two times higher than their wt controls were due to liver

dysfunction, we analyzed serum liver profiles and liver pathology in a subgroup of the mice included in the MRS analysis. These analyses revealed typical liver histology with no signs of portosystemic shunt in four Q84/Q84 mice (data not shown), and normal levels of liver analytes in mice of both genotypes (Supplementary Table 3) except in one wt mouse that showed bile acids $>250 \mu\text{mol/L}$, but normal liver H/E histology (data not shown), thereby excluding liver dysfunction as the cause of the detected high levels of Gln in Q84/Q84 transgenic mice.

Cerebellar neurometabolite profiles of Q135 mice (N=7), with CAG repeat length ranging from 125 and 129 trinucleotides (Supplementary Table 1), revealed significantly lower levels of tNAA, NAA, Glu, myo-Ins, GSH, and tCho compared to controls (N=7) (Figure 2A,B). Similar to the Q84/Q84 mice, the same neurochemical trends were observed in male and female Q135 mice analyzed separately (Supplementary Figure 2). Therefore, lower NAA and tNAA, tCho and myo-Ins represent the common neurochemical abnormalities in both SCA3 models (Supplementary Figure 3). In addition, groups of Q84/Q84 and Q135 mice were separated from wt controls with little or no overlap by plotting concentrations of these metabolites against each other (Figure 1C,2C).

SCA3 transgenic mice show depletion of myelin basic protein (MBP) and neurofilament medium (NFL) in cerebellar extracts and slices and thinning of the molecular layer

Because the three neurochemicals that allowed clear separation of both SCA3 transgenic mouse models from their respective controls suggest disturbances in the metabolism of membrane and myelin phospholipids^{59, 60} (myo-Ins and Cho) and neuroaxonal pathology⁶¹

(NAA), and were all decreased in cerebella of SCA3 mice, we investigated whether these mice show cerebellar demyelination and axonal atrophy (Figure 3).

Immunoblot analysis of cerebellar protein extracts from a subset (N=5 per group, 3F/2M) of the mice used to obtain neurochemical profiles (Figure 3A,D) revealed that the levels of MBP were indeed reduced to 31% of wt levels in Q84/Q84 mice (Figure 3B) and to 35% of wt levels in Q135 mice (Figure 3E). NFL abundance was also reduced to 13% of wt levels in cerebella of Q84/Q84 mice (Figure 3C) and to 11% of wt levels in Q135 mice (Figure 3F). Decreased cerebellar levels of MBP and NFL in Q84/Q84 and Q135 mice compared to controls were further evidenced by immunolabeling of these two proteins in cerebellar slices of these mice (N=4 animals per group) (Figure 3G). Triple immunofluorescence staining of MBP, NFL, and ATXN3 in cerebella of this subset of mice further revealed significantly thinner molecular layer in Q84/Q84 and Q135 mice than wt littermates (Supplementary Figure 4A), and a similar number of Purkinje cells in the primary fissure folia of mice from all genotypes (Supplementary Figure 4B).

***In vivo* myelin and neuronal markers measured by MRS correlate with *post-mortem* myelin and neuronal markers in SCA3 transgenic mice**

We next sought to determine if levels of tCho and/or myo-Ins are indicators of the status of myelination and if tNAA levels reflect axon integrity in the cerebellum. Hence, we investigated correlations between the levels of these neurochemicals with abundance of MBP and NFL proteins in the two SCA3 mouse models (Figure 3H,I, Supplementary Figure 5). Because of the small sample size per genotype group, correlation analyses were performed combining data

from transgenic mice and corresponding wt littermates for each SCA3 transgenic mouse strain. Concentration of tCho correlated significantly with MBP levels ($R^2=0.928$, $P<0.001$) (Figure 3H) and levels of tNAA correlated significantly with NFL expression in Q135 mice ($R^2=0.656$, $P=0.004$) (Figure 3I). To test if the significance of tCho-MBP and tNAA-NFL correlations in Q135 mice was due to a genotype clustering effect we repeated the correlation analyses adjusting for the genotype. While both correlations remained significant adjusting for genotype (tCho-MBP, $R^2=0.929$, $P=0.000$; tNAA-NFL, $R^2=0.658$, $P=0.023$), we verified that MBP and tCho concentrations correlated independently of the genotype, and that NFL correlated with tNAA levels due to a combined effect of tNAA and genotype. No correlation was found between tCho and MBP levels, and tNAA and NFL concentrations in Q84/Q84 mice (Supplementary Figure 5B,D), or between myo-Ins and MBP levels in either mouse model (Supplementary Figure 5A,C).

MBP and NFL are lower in the cerebellar cortex of patients with SCA3 than healthy controls

To investigate whether dysregulation of cerebellar MBP and NFL in the two SCA3 transgenic mouse models reflects the human SCA3 condition, we assessed levels of these proteins in samples from cerebellar cortex of patients with SCA3 and healthy controls (Supplementary Table 2). Levels of MBP were decreased to 9% of control levels and NFL to 19% of control levels in cerebellar cortex of patients with SCA3 (Figure 4A-C) indicating demyelination and axonopathy in this brain region. Luxol fast blue staining of brains from patients with SCA3 and

aged-matched unaffected individuals confirmed extensive demyelination in cerebella of patients with SCA3 that is more evident in aged patients (Figure 4D).

Long-term sustained reduction of mutant ATXN3 rescues cerebellar myelination and neurofilament biomarkers in homozygous Q84/Q84 mice

Because approaches to reduce levels of *ATXN3* gene products are currently a promising candidate therapy for SCA3, we sought to evaluate whether long-term sustained RNAi-mediated decrease of mutant human *ATXN3* (hATXN3) abundance in Q84/Q84 cerebella would prevent reduction of MBP and NFL. Therefore, we used cerebellar protein extracts from end-stage Q84/Q84 mice that were injected at 6-8 weeks-of-age in the DCN with an AAV encoding an artificial microRNA targeting mutant *ATXN3* (miRATXN3)³¹. We previously showed that miRATXN3 reduced hATXN3 levels to ~40% of vehicle-injected Q84/Q84 mice³¹. Cerebella of miRATXN3-treated Q84/Q84 mice in fact showed MBP and NFL levels of, respectively, 137% and 177% than their levels in vehicle-treated Q84/Q84 mice (Figure 5A,B). Whereas no association was detected between MBP and hATXN3 levels ($P=0.218$) (Figure 5C), NFL levels were significantly correlated with levels of mutant hATXN3, demonstrating an association between the level of gene silencing and the extent of rescue of neuroaxonal pathology in miRATXN3-treated Q84/Q84 mice ($P=0.006$) (Figure 5D).

Discussion

Future human clinical trials that seek to successfully translate preclinical animal studies would be facilitated by validated imaging biomarkers of cerebellar pathology. Here we identified shared neurochemical abnormalities in the homozygous Q84/Q84^{31, 42} and hemizygous Q135⁴³ transgenic mice. Both of these models are well characterized models, reproduce several aspects of SCA3, and are extensively used in preclinical trials. We have further demonstrated associations of these noninvasive MR markers with protein markers of neuroaxonal pathology and demyelination, as well as the reversibility of these pathologies with mutant *ATXN3* gene silencing.

Previously cerebral and cerebellar metabolic alterations were only reported in one study that used *in vitro* ¹H-MRS in brain tissue obtained from hemizygous Q84 mice⁶². The cerebellar neurometabolite spectra of homozygous Q84/Q84 mice showed similarities to the ones previously described in the *in vitro* study, namely higher Gln and lower NAA, tCho and myo-Ins in Q84/Q84 mice than wt controls⁶². Furthermore, the lower levels of tNAA observed in both models, lower levels of Glu in Q135 and higher levels of Gln in Q84/Q84 mice compared with controls, recapitulate prior observations in patients with SCA3^{39, 41}. Decrease of tNAA in the cerebellum is a common biomarker of neuronal dysfunction or loss displayed by patients affected with several SCAs (SCA1, SCA2, SCA3/MJD, SCA6, and SCA7)^{39, 41, 63, 64}, SCA1 mouse models^{44, 45, 65}, and hemizygous Q84 mice⁶². The decreased Glu levels detected suggests dysfunction of glutamatergic granule cells, unipolar brush cells (UBCs), and/or parallel and climbing fibers in the cerebellar cortex⁶⁶. While the number or function of these glutamatergic cells has not been investigated in cerebellar lobules of Q135 or Q84/Q84 mice, Purkinje cells (PCs) show decreased calbindin staining in Q135 mice³⁵ and electrophysiological

alterations in Q84 mice⁵³ indicating that these cells are somehow dysfunctional. Because PCs receive excitatory input from parallel and/or climbing fibers, it is possible that Q135 PCs are impaired due to decreased input from these fibers into the molecular layer. End-stage Q84/Q84 cerebella did not show decreased levels of Glu, but displayed increased concentration of Gln, which could suggest abnormal Glu-Gln cycle between glutamate cells and Bergmann glia in the molecular layer, and/or a higher number of glial cells that produce the bulk of Gln in the brain. While cerebellar cell loss in aged SCA3 mice needs to be further investigated, thinning of the molecular layer accompanied by preserved Purkinje cell number in these mice suggests that dysregulated levels of tNAA, Glu and Gln reflect neuronal dysfunction and dendritic atrophy rather than cell loss in these models, similar to prior observations in SCA1 models⁴⁴.

In addition to the above described neurochemical changes in SCA3 mice, each of the transgenic mouse groups showed a clear separation from their respective wild type controls in concentrations of tNAA, myo-Ins and tCho in the cerebellum (Figures 1C, 2C, Supplementary Figure 3). NAA is a validated marker of neuronal viability⁶¹ and a source of acetate for myelin lipid synthesis in oligodendrocytes⁶⁷, myo-Ins is a structural sugar of membrane and myelin phospholipids³⁹, and changes in tCho levels reflect disturbances in phospholipid metabolism⁶⁷. Because all three metabolites were decreased in spectra of both SCA3 mouse models, we hypothesized that these mice would display cerebellar demyelination and axon atrophy. Demyelination, white matter and axon dysfunction and axonopathy have indeed been reported histopathologically in brain tissue obtained from patients with SCA3^{17, 40, 41}, and primary oligodendrocyte/myelin dysfunction indicated by diffusion MRI in SCA3¹⁴. Furthermore, altered function of oligodendrocytes was recently reported in SCA3 models including the Q84⁶⁸. Here,

by showing that aged Q84/Q84 and Q135 cerebella and post-mortem cerebellar cortex from patients with SCA3 display reduced levels of MBP and NFL compared to their respective controls, we confirmed demyelination and axon loss in SCA3 cerebella. The magnitude of reduction that we detected in NFL in SCA3 cerebella relative to controls was markedly higher than the reduction in the *in vivo* neuronal marker, tNAA. Similarly, the magnitude of reduction in MBP in SCA3 was substantially higher than the % reduction in the MRS markers myo-Ins and tCho. This is likely because these neurochemicals have multiple roles, such as serving as metabolic intermediates and osmolytes, and therefore are less specific for neuroaxonal and myelin pathology than the *post-mortem* protein markers. However, importantly, the associations between tCho with MBP levels and tNAA with NFL abundance in the Q135 mice suggest that tCho and tNAA levels reflect the status of myelination and axon integrity in the cerebellum of these mice. This evidence supports the inclusion of MRS evaluation of these neurochemicals in preclinical trials using Q84/Q84 and Q135 mice to evaluate the efficacy of therapeutic agents in rescuing SCA3 pathology.

While MBP levels were higher in miRATXN3-treated Q84/Q84 cerebella than wt controls, concentrations of MBP and hATXN3 did not correlate, possibly indicating that AAV2/1 miRATXN3 poorly transduced oligodendrocytes, as expected for this virus serotype⁶⁹. Cerebellar axon loss seems to be, however, a consequence of expression of toxic expanded ATXN3 since reduction of NFL concentration in Q84/Q84 cerebella was suppressed by long-term decrease of mutant *ATXN3* levels in miRATXN3-treated Q84/Q84 mice. NFL levels significantly correlated with hATXN3 abundance in the cerebella of Q84/Q84 mice suggesting that AAV2/1 miRATXN3 effectively transduced and reduced hATXN3 in the majority of

cerebellar neurons. Importantly, the reversal of the neuroaxonal pathology with RNAi-mediated reduction of ATXN3 levels supports the use of noninvasive imaging markers of this pathology in future pre-clinical and clinical trials that evaluate similar gene silencing strategies. No MRS measurements are available for this set of RNAi-treated SCA3 mice³¹. Whether gene silencing will rescue the abnormal levels of the myelin and neuronal markers measured by MRS, similar to prior observations in SCA1 mice⁷⁰, remains to be determined in future studies.

The ultra-high field strength MRI scanner we used in this study is not widely available for human trials that will like utilize the widely available 3T platform. We previously demonstrated the feasibility of detecting neurochemical alterations in patients with SCAs at field strengths ranging from 3-7T^{39, 41, 63, 64, 71}. Specifically, neurochemical abnormalities were reliably detected in SCA3 at 3T³⁹. Thus, the current observations in SCA3 models can be obtained with 3T technology when similar optimized methods are used for MRS data acquisition and analysis. We have further shown good test-retest reproducibility of cerebellar neurochemical concentrations at 3T⁷² and the two-site reproducibility of cerebellar and brainstem neurochemical concentrations at 3T⁷³. Finally, these MRS methods are now being validated for clinical trial readiness in SCA3 in an international, multi-site setting (<https://readisca.org/>).

In summary, we have identified novel neurochemical and molecular similarities between end-stage homozygous Q84/Q84, aged hemizygous Q135 mice, and patients with SCA3, further supporting the use of these mouse models in preclinical trials of SCA3. Like patients with SCA3, both transgenic models show neurochemical signatures indicative of neuronal dysfunction, dysregulation of glutamatergic systems, and myelin and neurite loss. We also provide molecular confirmation of cerebellar myelin and axon damage in SCA3 mice and

patients and establish significant associations of select neurochemical markers with invasive measures of myelin and axon damage. It will be important to perform future longitudinal MRS, molecular and pathological studies in parallel to evaluate the progression of neurometabolite dysregulation and associated molecular and pathological outcomes in the cerebellum and other SCA3-affected brain areas of transgenic mice. These novel neurochemical alterations in SCA3 transgenic mice reflect important aspects of pathology and should enable noninvasive monitoring of pathology reversal in future preclinical trials of therapeutic agents for SCA3.

Acknowledgements

The authors thank Dr. Sujith V. Weerasinghe and Dr. M. Bishr Omary for help with the liver studies, the Michigan Brain Bank (5P30 AG053760 University of Michigan Alzheimer's Disease Core Center) and its coordinator Mathew Perkins for providing brain samples of MJD patients and control individuals, and Dr. Lynn Eberly for statistical consulting. This work was funded by: Portuguese National funds, through the Foundation for Science and Technology (FCT) - projects UIDB/50026/2020 and PTDC/NEU-NMC/3648/2014, and by FEDER funds, through the Competitiveness Factors Operational Programme (COMPETE) and the Northern Portugal Regional Operational Program (NORTE 2020), under the Portugal 2020 Partnership Agreement - projects NORTE-01-0145-FEDER-000013 and POCI-01-0145-FEDER-016818 to P.M.; NIH/NINDS R01NS03871 to H.L.P.; NIH/NINDS R21 NS111154 to H.S.M. and G.Ö; and a Becky Babcox Research Fund pilot research award, University of Michigan, to M.C.C.. The Center for Magnetic Resonance Research is supported by the National Institute of Biomedical

Imaging and Bioengineering (NIBIB) grant P41 EB027061, the Institutional Center Cores for Advanced Neuroimaging award P30 NS076408 and the W.M. Keck Foundation.

Authors' Roles (1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique)

M.C.C.: 1) A, B, C; 2) A, B, C; 3) A, B

M.R.: 1) C

H.S.M.: 1) A, C; 3) B

N.S.A.: 1) C

S.F.: 1) C

V.G.S.: 1) A, B; 3) B

P.M.: 1) A, B; 3) B

H.L.P.: 1) A; 3) B

G.O.: 1) A, B, C; 2) A, B, C; 3) A, B

Financial disclosures

The authors declare no competing interests.

Figure Legends

Figure 1: Cerebellar neurochemical levels are altered in homozygous Q84/Q84 mice. A)

Representative localized proton MR spectra and midsagittal T₂-weighted images of a Q84/Q84 and a wt littermate mouse. The most prominent neurochemical abnormalities, namely lower tCho and higher Gln in Q84/Q84 compared to wt mice, are denoted in the spectra by arrows. **B)** Cerebellar neurochemical profiles of Q84/Q84 mice (N=12, black bars) and wt littermates (N=11, white bars). Bars represent average neurochemical concentration \pm SEM. Comparison between mouse genotypes was performed using Student's t-test and statistical significance is indicated as: * P <0.05, ** P <0.01, and *** P <0.001. **C)** Separation of Q84/Q84 mice (black squares) from controls (white squares) by plotting two altered metabolites against each other.

Figure 2: Cerebellar neurochemical levels are altered in hemizygous Q135 mice. A)

Representative localized proton MR spectra and midsagittal T₂-weighted images of a Q135 and a wt littermate mouse. The most prominent neurochemical abnormalities, namely lower tCho and tNAA in Q135 compared to wt mice, are denoted in the spectra by arrows. **B)** Cerebellar neurochemical profiles of Q135 mice (N=7, grey bars) and wt littermates (N=7, white bars). Bars represent average chemical concentration \pm SEM. Comparison between mouse genotypes was performed using Student's t-test and statistical significance is indicated as: * P <0.05, ** P <0.01, and *** P <0.001. **C)** Separation of Q135 mice (grey squares) from controls (white squares) by plotting two altered metabolites against each other.

Figure 3: Cerebella of SCA3 transgenic mice show decreased levels of myelin basic protein (MBP) and neurofilament medium (NFL) that correlate with concentrations of

tCho and tNAA, respectively, in Q135 mice. A,D) Anti-ATXN3 immunoblot (anti-MJD antibody) detecting mutant human ATXN3 and endogenous mouse Atxn3 in cerebellar soluble protein extracts of the subset of Q84/Q84 (**A**), Q135 (**D**) and corresponding littermate wild type mice used to assess levels of MBP (**B,E**) and NFL medium (NFL) (**C,F**). Western blots show decreased levels of MBP and NFL in cerebella of Q84/Q84 (**B,C**) and Q135 (**E,F**) compared with controls. Graphs show quantification of protein bands by densitometry. Bars represent the average percentage of protein relative to respective wild type controls, normalized for α -Tubulin (\pm SEM). Statistical significance determined by Student's t-test is indicated as $*P<0.05$. **G**) Representative images of immunofluorescent labelling of MBP (red) and NFL (green) show decreased signal of these two proteins in cerebella of Q84/Q84 and Q135 mice compared with corresponding litter mates (N=4 mice per group). Nuclei were labeled with DAPI (blue). Scale bar, 100 μ m. **H, I**) Plots showing Pearson correlations of levels of MBP with tCho (**H**), and NFL with tNAA (**I**) in Q135 (grey circles), and their respective wt littermate mice (white circles).

Figure 4: Cerebellar lobules of patients with SCA3 show decreased levels of MBP and NFL medium and demyelination. A) Anti-ATXN3 immunoblot (anti-MJD antibody) detecting expanded and normal ATXN3 in soluble protein extracts from cerebellar cortex of patients with SCA3 and control individuals. Detection of MBP (**B**) and NFL medium (**C**) by Western blotting shows lower levels of both proteins in patients compared with controls. Graphs show quantification of protein bands by densitometry. Bars represent the average percentage of protein relative to respective wild type controls, normalized for α -Tubulin (\pm SEM). Statistical significance determined by Student's t-test is indicated as $*P<0.05$. **D)** Luxol fast blue staining

of cerebellar sections shows signs of demyelination in patients with SCA3 compared with aged-matched unaffected individuals, which is more evident in older patients. Scale bar, 200 μ m.

Figure 5: Cerebella from miRATXN3-treated Q84/Q84 show higher levels of MBP and NFL medium compared to vehicle-treated Q84 animals. Immunoblotting to detect MBP (A) and NFL (B) in cerebellar soluble protein extracts from end-stage Q84/Q84 mice injected with an adeno-associated virus delivering an artificial microRNA targeting ATXN3 transcripts (miRATXN3) or injected with vehicle. Graphs show quantification of protein bands by densitometry. Bars represent the average percentage of protein relative to levels in vehicle-injected Q84/Q84 mice, normalized for α -Tubulin (\pm SEM). Black and blue bars indicate, respectively, vehicle-injected and miRATXN3-injected Q84/Q84 mice. Statistical significance determined by Student's t-test is indicated as $**P < 0.01$. Plots showing Pearson correlations of levels of MBP with hATXN3 (C) and of NFL with hATXN3 (D) in vehicle (black circles) or miRATXN3 (blue circles) treated Q84/Q84 mice.

References

1. La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. *Nat Rev Genet* 2010;11(4):247-258.
2. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. *Annu Rev Neurosci* 2007;30:575-621.
3. Ashizawa T, Oz G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. *Nat Rev Neurol* 2018;14(10):590-605.
4. Buijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. *Neurotherapeutics* 2019.
5. Karam A, Trottier Y. Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7. *Adv Exp Med Biol* 2018;1049:197-218.

6. Lane RM, Smith A, Baumann T, et al. Translating Antisense Technology into a Treatment for Huntington's Disease. *Methods Mol Biol* 2018;1780:497-523.
7. Singh K, Roy I. Nucleic acid therapeutics in Huntington's disease. *Recent Pat Biotechnol* 2019.
8. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. *N Engl J Med* 2019;380(24):2307-2316.
9. Da Silva JD, Teixeira-Castro A, Maciel P. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation. *Neurotherapeutics* 2019.
10. Duarte-Silva S, Maciel P. Pharmacological Therapies for Machado-Joseph Disease. *Adv Exp Med Biol* 2018;1049:369-394.
11. Paulson HL, Shakkottai VG, Clark HB, Orr HT. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. *Nat Rev Neurosci* 2017;18(10):613-626.
12. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nat Genet* 1994;8(3):221-228.
13. Costa Mdo C, Paulson HL. Toward understanding Machado-Joseph disease. *Prog Neurobiol* 2012;97(2):239-257.
14. Guimaraes RP, D'Abreu A, Yasuda CL, et al. A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. *Mov Disord* 2013;28(8):1125-1132.
15. Linnemann C, Tezenas du Montcel S, Rakowicz M, et al. Peripheral Neuropathy in Spinocerebellar Ataxia Type 1, 2, 3, and 6. *Cerebellum* 2016;15(2):165-173.
16. Rezende TJR, de Paiva JLR, Martinez ARM, et al. Structural signature of SCA3: From presymptomatic to late disease stages. *Ann Neurol* 2018;84(3):401-408.
17. Rub U, Schols L, Paulson H, et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. *Prog Neurobiol* 2013;104:38-66.
18. Seidel K, Siswanto S, Brunt ER, den Dunnen W, Korf HW, Rub U. Brain pathology of spinocerebellar ataxias. *Acta Neuropathol* 2012;124(1):1-21.
19. Suga N, Katsuno M, Koike H, et al. Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3. *Neuropathol Appl Neurobiol* 2014;40(5):628-639.
20. Wu X, Liao X, Zhan Y, et al. Microstructural Alterations in Asymptomatic and Symptomatic Patients with Spinocerebellar Ataxia Type 3: A Tract-Based Spatial Statistics Study. *Front Neurol* 2017;8:714.
21. McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. *Neurobiol Dis* 2019;134:104635.
22. Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. *Neurology* 1978;28(7):703-709.
23. Lima L, Coutinho P. Clinical criteria for diagnosis of Machado-Joseph disease: report of a non-Azorena Portuguese family. *Neurology* 1980;30(3):319-322.
24. Paulson H. Spinocerebellar Ataxia Type 3. 1993.
25. Riess O, Rub U, Pastore A, Bauer P, Schols L. SCA3: neurological features, pathogenesis and animal models. *Cerebellum* 2008;7(2):125-137.
26. Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. *Mov Disord* 1992;7(3):193-203.

27. McLoughlin HS, Moore LR, Chopra R, et al. Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice. *Ann Neurol* 2018.
28. Toonen LJA, Rigo F, van Attikum H, van Roon-Mom WMC. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. *Mol Ther Nucleic Acids* 2017;8:232-242.
29. Kourkouta E, Weij R, Gonzalez-Barriga A, et al. Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide. *Mol Ther Nucleic Acids* 2019;17:601-614.
30. Moore LR, Rajpal G, Dillingham IT, et al. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. *Mol Ther Nucleic Acids* 2017;7:200-210.
31. do Carmo Costa M, Luna-Cancelon K, Fischer S, et al. Toward RNAi Therapy for the Polyglutamine Disease Machado-Joseph Disease. *Mol Ther* 2013;21(10):1898-1908.
32. Nobrega C, Nascimento-Ferreira I, Onofre I, et al. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in machado-joseph disease transgenic mice. *PLoS One* 2013;8(1):e52396.
33. Ashraf NS, Duarte-Silva S, Shaw ED, et al. Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. *Mol Neurobiol* 2018.
34. Esteves S, Oliveira S, Duarte-Silva S, Cunha-Garcia D, Teixeira-Castro A, Maciel P. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. *Mol Neurobiol* 2018.
35. Teixeira-Castro A, Jalles A, Esteves S, et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. *Brain* 2015;138(Pt 11):3221-3237.
36. Adanyeguh IM, Perlberg V, Henry PG, et al. Autosomal dominant cerebellar ataxias: Imaging biomarkers with high effect sizes. *Neuroimage Clin* 2018;19:858-867.
37. D'Abreu A, Franca Jr MC, Yasuda CL, Campos BA, Lopes-Cendes I, Cendes F. Neocortical Atrophy in Machado-Joseph Disease: A Longitudinal Neuroimaging Study. *J Neuroimaging* 2011;doi: 10.1111/j.1552-6569.2011.00614.x.
38. Reetz K, Costa AS, Mirzazade S, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. *Brain* 2013;136(Pt 3):905-917.
39. Adanyeguh IM, Henry PG, Nguyen TM, et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. *Mov Disord* 2015;30(5):662-670.
40. D'Abreu A, Franca M, Jr., Appenzeller S, Lopes-Cendes I, Cendes F. Axonal dysfunction in the deep white matter in Machado-Joseph disease. *J Neuroimaging* 2009;19(1):9-12.
41. Joers JM, Deelchand DK, Lyu T, et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. *Ann Neurol* 2018;83(4):816-829.
42. Cemal CK, Carroll CJ, Lawrence L, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. *Hum Mol Genet* 2002;11(9):1075-1094.
43. Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, et al. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. *Neurotherapeutics* 2014;11(2):433-449.

44. Oz G, Nelson CD, Koski DM, et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. *J Neurosci* 2010;30(10):3831-3838.
45. Oz G, Vollmers ML, Nelson CD, et al. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. *Exp Neurol* 2011;232(2):290-298.
46. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. *Magn Reson Med* 1986;3(6):823-833.
47. Gruetter R, Tkac I. Field mapping without reference scan using asymmetric echo-planar techniques. *Magn Reson Med* 2000;43(2):319-323.
48. Garwood M, DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. *J Magn Reson* 2001;153(2):155-177.
49. Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-voxel magnetic resonance spectroscopy: experts' consensus recommendations. *NMR Biomed* 2020:e4257.
50. Klose U. In vivo proton spectroscopy in presence of eddy currents. *Magn Reson Med* 1990;14(1):26-30.
51. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. *Magn Reson Med* 1993;30(6):672-679.
52. Provencher SW. Automatic quantitation of localized in vivo ¹H spectra with LCModel. *NMR Biomed* 2001;14(4):260-264.
53. Shakkottai VG, do Carmo Costa M, Dell'orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. *J Neurosci* 2011;31(36):13002-13014.
54. Duarte-Silva S, Neves-Carvalho A, Soares-Cunha C, et al. Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease. *Cerebellum* 2014.
55. Esteves S, Oliveira S, Duarte-Silva S, Cunha-Garcia D, Teixeira-Castro A, Maciel P. Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease. *Mol Neurobiol* 2019;56(5):3626-3637.
56. McLoughlin HS, Moore LR, Chopra R, et al. Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. *Ann Neurol* 2018;84(1):64-77.
57. Cudalbu C, McLin VA, Lei H, et al. The C57BL/6J mouse exhibits sporadic congenital portosystemic shunts. *PLoS One* 2013;8(7):e69782.
58. Emir UE, Brent Clark H, Vollmers ML, Eberly LE, Oz G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. *J Neurochem* 2013;127(5):660-668.
59. Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. *J Neurochem* 2002;82(4):736-754.
60. Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: the past, present and future. *Chem Rev* 2010;110(5):3060-3086.
61. Demougeot C, Garnier P, Mossiat C, et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. *J Neurochem* 2001;77(2):408-415.

62. Griffin JL, Cemal CK, Pook MA. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. *Physiological Genomics* 2004;16:334-340.
63. Oz G, Hutter D, Tkac I, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. *Mov Disord* 2010;25(9):1253-1261.
64. Oz G, Iltis I, Hutter D, Thomas W, Bushara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. *Cerebellum* 2011;10(2):208-217.
65. Oz G, Kittelson E, Demirgoz D, et al. Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology. *Neurobiol Dis* 2015;74:158-166.
66. Hoshino M. Neuronal subtype specification in the cerebellum and dorsal hindbrain. *Dev Growth Differ* 2012;54(3):317-326.
67. Xu H, Zhang H, Zhang J, Huang Q, Shen Z, Wu R. Evaluation of neuron-glia integrity by in vivo proton magnetic resonance spectroscopy: Implications for psychiatric disorders. *Neurosci Biobehav Rev* 2016;71:563-577.
68. Ramani B, Panwar B, Moore LR, et al. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes. *Hum Mol Genet* 2017;26(17):3362-3374.
69. Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. *Mol Ther* 2009;17(10):1692-1702.
70. Friedrich J, Kordasiewicz HB, O'Callaghan B, et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. *JCI Insight* 2018;3(21).
71. Deelchand DK, Joers JM, Ravishankar A, et al. Sensitivity of Volumetric Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy to Progression of Spinocerebellar Ataxia Type 1. *Mov Disord Clin Pract* 2019;6(7):549-558.
72. Terpstra M, Cheong I, Lyu T, et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. *Magn Reson Med* 2016;76(4):1083-1091.
73. Deelchand DK, Adanyeguh IM, Emir UE, et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. *Magn Reson Med* 2015;73(5):1718-1725.

COPYRIGHT TRANSFER AGREEMENT

Date: 05/05/2020

Contributor name: Naila Ashraf

Contributor address: 2101 Vine Way Drive Unit 93 Canton, MI 48188

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

Naila Ashraf 05/05/2020
Contributor's signature Date

Naila Ashraf Research Technician
Type or print name and title

Co-Contributor's signature Date

Type or print name and title

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):


Name: _____

Address: _____


Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY



MDS_28140_Figure 3.tif



MDS_28140_Figure 5_compressed.tif

COPYRIGHT TRANSFER AGREEMENT

Date: 5/4/2020

Contributor name: Vikram Shakkottai

Contributor address: 4009 BSRB, 109 Zina Pitcher Pl.
Ann Arbor MI 48109

Manuscript number: MDS-20-0241

Re: Manuscript entitled: *In vivo* molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3
(the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

Contributor's signature	Date
Type or print name and title	Date
Co-Contributor's signature	Date
Type or print name and title	

[] Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: UptoDate Inc

Address: Wolters Kluwer

Type of support: Royalties

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 05/04/2020

Contributor name: Hayley S. McLoughlin

Contributor address: 4017 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48108

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

<input checked="" type="checkbox"/> Contributor-owned work	<u>Hayley S. McLoughlin</u>	<u>05/04/2020</u>
	Contributor's signature	Date
	<u>Hayley S. McLoughlin, PhD</u>	
	Type or print name and title	
	<u></u>	<u></u>
	Co-Contributor's signature	Date
	<u></u>	
	Type or print name and title	

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Hayley S. McLoughlin

Address: 4017 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48108

Type of support: NINDS R21 NIH

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Hayley S. McLoughlin

Address: 4017 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI 48108

Type of support: NINDS NIH (U01), UMich internal grant, and NAF grants;
industry sponsored research with UniQure

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: May 4, 2020

Contributor name: Henry Paulson MD PhD

Contributor address: University of Michigan, Dept. Neurology

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

<input checked="" type="checkbox"/>	Contributor-owned work	<u>Henry L. Paulson</u>	<u>5/4/2020</u>
		Contributor's signature	Date
		<u>Henry L. Paulson MD PhD</u>	
		Type or print name and title	
		<u></u>	<u></u>
		Co-Contributor's signature	Date
		<u></u>	
		Type or print name and title	

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Henry L. Paulson MD PhD

Address: University of Michigan, Dept. Neurology

Type of support: NIH R01NS038712

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Henry L. Paulson MD PhD

Address: University of Michigan, Dept. Neurology

Type of support: NIH R01NS096785, U01NS106670, U01NS104326, 1P30AG053760

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 5/4/2020

Contributor name: Gulin Oz

Contributor address: CMRR, 2021 6th St. SE, Minneapolis, MN 55455

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

Gulin Oz
Contributor's signature

5/4/2020
Date

Gulin Oz, Professor
Type or print name and title

Co-Contributor's signature

Date

Type or print name and title

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: NIH

Address: _____

Type of support: grant

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: NIH, National Ataxia Foundation, Biogen, Inc.

Address: _____

Type of support: grant

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 5/4/2020

Contributor name: Maria do Carmo Costa

Contributor address: 109 Zina Pitcher Place, BSRB room 4027, Ann Arbor, MI 48109, USA

Manuscript number: MDS-20-0241

Re: Manuscript entitled: *In vivo* molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

<input checked="" type="checkbox"/> Contributor-owned work	<u>Maria do Carmo Costa</u>	<u>05/04/2020</u>
	Contributor's signature	Date
	<u>Maria do Carmo Costa, PhD</u>	
	Type or print name and title	
	<u></u>	<u></u>
	Co-Contributor's signature	Date
	<u></u>	
	Type or print name and title	

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Becky Babcox Research Fund, University of Michigan

Address: _____

Type of support: Pilot research grant

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: NINDS/NIH; National Ataxia Foundation (NAF); Alnylam Pharmaceuticals; Exicure Inc.

Address: _____

Type of support: Co-Investigator with effort in NIH grants; NAF grant; Sponsored Research Agreements with Alnylam Pharmaceuticals and with Exicure Inc.

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 5/4/20

Contributor name: Maria Radzwion

Contributor address: 2408 Dallas Ave Royal Oak, MI 48067

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3
(the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

Maria Radzwion
Contributor's signature

5/4/20
Date

Maria Radzwion BSc
Type or print name and title

Co-Contributor's signature

Date

Type or print name and title

[] Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: 5/4/2020

Contributor name: Svetlana Fischer

Contributor address: 109 Zina Pitcher Pl, 4178 BSRB, Ann Arbor, MI 48109

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal's online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

S Fischer 5/4/2020
Contributor's signature Date

Svetlana Fischer / Research Lab Specialist
Type or print name and title

Co-Contributor's signature Date

Type or print name and title

Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _____

Address: _____

Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

COPYRIGHT TRANSFER AGREEMENT

Date: May 6th 2020

Contributor name: Patrícia Maciel

Contributor address: University of Minho

Manuscript number: MDS-20-0241

Re: Manuscript entitled: In vivo molecular signatures of cerebellar pathology in spinocerebellar ataxia type 3 (the "Contribution")

for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor's employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic "preprints" of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor's nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor's own personal website, on the Contributor's internal intranet at Contributor's nonprofit organization or educational institution, or on a secure external website at the Contributor's nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor's non-profit organization or educational institution. Contributor shall not charge a fee for any

preprints, and Contributor's use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal's website, located at <http://www.interscience.Wiley.com>. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the "Accepted Version") is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: <http://www.wiley.com/go/funderstatement>.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: <http://www.wiley.com/go/funderstatement>. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

- a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
- b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner's OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution's repository after the following applicable embargo period has expired. See the following website for details: <http://olabout.wiley.com/WileyCDA/Section/id-817011.html>.

D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor's employment (as a "work-made-for-hire" in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor's signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR'S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor's original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal's Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) ("patient identifiable content"), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)' physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 ("HIPAA") if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.

I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

Contributor-owned work

Patricia Maciel May 6th 2020
Contributor’s signature Date

PROF. PATRÍCIA MACIEL
Type or print name and title

Co-Contributor’s signature Date

Type or print name and title

[] Company/Institution-owned Work (made-for-hire in the Course of employment) _____
Company or Institution (Employer-for-Hire) _____ Date _____

Authorized signature of Employer _____ Date _____

Contributor's signature _____ Date _____

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[] **U.S. Government work**

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[] **U.K. Government work (Crown Copyright)**

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[] **Other**

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _____

Address: _____

Type of support: _____

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):


Name: _____

Address: _____


Type of support: _____

This material will be posted on the journal website and may be printed at the Editors' discretion.


ATTACH ADDITIONAL INFORMATION AS NECESSARY



MDS_28140_NEW Figure 1_compressed.tif



MDS_28140_NEW Figure 2_compressed.tif



MDS_28140_NEW Figure 4 (option 1)_compressed.tif